Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b

J. Genesca; J. I. Esteban; J. Quer; L. L. Viladomiu; A. Gonzalez; R. Esteban; J. Guardia

doi:10.1136/gut.34.2_Suppl.S62

Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b

J. Genesca^*, J. I. Esteban, J. Quer, L. L. Viladomiu, A. Gonzalez, R. Esteban, J. Guardia

^*Autor corresponent d’aquest treball

Hospital Universitari Vall d'Hebron (HUVH)

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

14 Cites (Scopus)

Resum

This trial was undertaken to establish the long term biochemical and serological outcome of patients with acute posttransfusion hepatitis C virus infection after treatment with interferon alfa-2b. After 12 months, 12 patients (eight treated, four controls) had self limited disease and 16 patients (seven treated, nine controls) had chronic disease. After a total mean 31 months of follow up in 23 patients, nine (six treated, three controls) had self limited disease while 14 (five treated, nine controls) developed chronic liver disease; all patients with spontaneous or selflimited hepatitis C (HCV) infection maintained normal serum alanine aminotransferase activity and absence of HCVRNA, and tended to lose anti-HCV antibodies.

Idioma original	Anglès
Pàgines (de-a)	S62-S63
Nombre de pàgines	2
Revista	Gut
Volum	34
Número	2 SUPPL
DOIs	https://doi.org/10.1136/gut.34.2_Suppl.S62
Estat de la publicació	Publicada - 1 de gen. 1993

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1136/gut.34.2_Suppl.S62

Altres arxius i enllaços

Enllaç a la publicació de Scopus

Com citar-ho

@article{aedc88b1af4b418f865d19251ca8e840,

title = "Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b",

abstract = "This trial was undertaken to establish the long term biochemical and serological outcome of patients with acute posttransfusion hepatitis C virus infection after treatment with interferon alfa-2b. After 12 months, 12 patients (eight treated, four controls) had self limited disease and 16 patients (seven treated, nine controls) had chronic disease. After a total mean 31 months of follow up in 23 patients, nine (six treated, three controls) had self limited disease while 14 (five treated, nine controls) developed chronic liver disease; all patients with spontaneous or selflimited hepatitis C (HCV) infection maintained normal serum alanine aminotransferase activity and absence of HCVRNA, and tended to lose anti-HCV antibodies.",

author = "J. Genesca and Esteban, {J. I.} and J. Quer and Viladomiu, {L. L.} and A. Gonzalez and R. Esteban and J. Guardia",

year = "1993",

month = jan,

day = "1",

doi = "10.1136/gut.34.2_Suppl.S62",

language = "English",

volume = "34",

pages = "S62--S63",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "2 SUPPL",

}

TY - JOUR

T1 - Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b

AU - Genesca, J.

AU - Esteban, J. I.

AU - Quer, J.

AU - Viladomiu, L. L.

AU - Gonzalez, A.

AU - Esteban, R.

AU - Guardia, J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - This trial was undertaken to establish the long term biochemical and serological outcome of patients with acute posttransfusion hepatitis C virus infection after treatment with interferon alfa-2b. After 12 months, 12 patients (eight treated, four controls) had self limited disease and 16 patients (seven treated, nine controls) had chronic disease. After a total mean 31 months of follow up in 23 patients, nine (six treated, three controls) had self limited disease while 14 (five treated, nine controls) developed chronic liver disease; all patients with spontaneous or selflimited hepatitis C (HCV) infection maintained normal serum alanine aminotransferase activity and absence of HCVRNA, and tended to lose anti-HCV antibodies.

AB - This trial was undertaken to establish the long term biochemical and serological outcome of patients with acute posttransfusion hepatitis C virus infection after treatment with interferon alfa-2b. After 12 months, 12 patients (eight treated, four controls) had self limited disease and 16 patients (seven treated, nine controls) had chronic disease. After a total mean 31 months of follow up in 23 patients, nine (six treated, three controls) had self limited disease while 14 (five treated, nine controls) developed chronic liver disease; all patients with spontaneous or selflimited hepatitis C (HCV) infection maintained normal serum alanine aminotransferase activity and absence of HCVRNA, and tended to lose anti-HCV antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0027214876&partnerID=8YFLogxK

U2 - 10.1136/gut.34.2_Suppl.S62

DO - 10.1136/gut.34.2_Suppl.S62

M3 - Article

C2 - 7686120

AN - SCOPUS:0027214876

SN - 0017-5749

VL - 34

SP - S62-S63

JO - Gut

JF - Gut

IS - 2 SUPPL

ER -

Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho